Kadmon Holdings, Inc. 8-K SEC Filings

SECTION 1. Annual Meetings. The annual meeting of the stockholders of Kadmon Holdings, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be...

On November 5, 2021, Kadmon Holdings, Inc. (the “Company”) held a special meeting of its stockholders (the “Special Meeting”) to consider and vote upon the following proposals (1) the merger of the Company with and into a wholly owned in...

– REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States –

This Form 8-K amends and supplements the Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) previously filed by Kadmon Holdings, Inc. (the “Company” or “we”) with the Securities and Exchange Commission on October 4, 2021,...

As previously disclosed, on September 7, 2021, Kadmon Holdings, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sanofi, a French societe anonyme (“Sanofi”) and Lato...

Exhibit B Certificate of Incorporation of the Surviving Corporation

NEW YORK, August 5, 2021 – Kadmon Holdings, Inc. (Nasdaq: KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021.

U.S. FDA Grants Full Approval of REZUROCK™ (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)

1.1 Establishment. The Amended and Restated Kadmon Holdings, Inc. 2016 Equity Incentive Plan (the “Plan”), established effective as of July 13, 2016, the date of its approval by the stockholders of the Company (the “Effective Date”), is ...

NEW YORK, May 6, 2021 – Kadmon Holdings, Inc. (Nasdaq: KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021.

NEW YORK, April 1, 2021 – Kadmon Holdings, Inc. (Nasdaq: KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company’s ROCK2 inhibitor, in patients with diffuse cutaneou...

NEW YORK, March 10, 2021 – Kadmon Holdings, Inc. (Nasdaq: KDMN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for belumosudil for the treatment of chron...

NEW YORK, March 4, 2021 – Kadmon Holdings, Inc. (Nasdaq: KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2020.

Exhibit A: Form of Note...........................................................................................................................................A-1

As used in this Exhibit 99.2, unless the context indicates otherwise, references to “Kadmon,” “the Company,” “we,” “us,” “our” and similar references refer to Kadmon Holdings, Inc. and its wholly owned subsidiaries.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

- ORRs of 73% and 77% with Belumosudil 200 mg QD and 200 mg BID, Respectively –

– FDA Grants Priority Review and Sets PDUFA Action Date of May 30, 2021 –

NEW YORK, November 5, 2020 – Kadmon Holdings, Inc. (Nasdaq: KDMN) today provided a business update and reported financial and operational results for the third quarter of 2020.

NEW YORK, October 13, 2020 – Kadmon Holdings, Inc. (NYSE: KDMN) announced today that it will voluntarily transfer its stock exchange listing from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market (“Nasdaq”). The Compa...